Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 01.05.2024 · 196 (05) · 482-490
DOI: 10.1055/a-2203-2733 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, erschienen am 01.05.2024. Verfasst von Thomas J Vogl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Microwaves, Radiofrequency Ablation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Purpose
To compare the therapeutic response and clinical outcome of CT-guided percutaneous microwave (MWA) and radiofrequency ablation (RFA) for the treatment of small- and medium-sized HCC. Materials and Methods In this prospective trial, 50 patients with HCC were randomly assigned to MWA or RFA treatment. MRI was performed 24 h before and after ablation and subsequently in 3-month intervals. Ablation volumes, ablation durations, adverse events (AE), technique efficacy, technical success, local tumor progression (LTP), disease-free survival (DFS), intrahepatic distant recurrence (IDR), and overall survival (OS) rates were evaluated.
Results
The mean ablation volume was 66.5 cm³ for MWA and 29.2 cm³ for RFA (p < 0.01). The mean ablation durations for MWA and RFA were 11.2 ± 4.0 min and 16.3 ± 4.7 min, respectively (p < 0.01). Six mild AEs were documented (p > 0.05). All treatments had a technical success rate and a technique efficacy rate of 100 % (50/50, p = 1.00). LTP within 2 years occurred in 1/25 (4 %) in the MWA group and in 4/25 (16 %) in the RFA group (p = 0.06). IDR within 2 years was 8/25 (32 %) for MWA and 14/25 (56 %) for RFA (p < 0.05). The median DFS was 24.5 months and 13.4 months for MWA and RFA, respectively (p = 0.02). The 1-, 2-, 3-year OS rates were 100 %, 80 %, 72 % in the MWA group and 72 %, 64 %, 60 % in the RFA group, respectively (p ≥ 0.14).
Conclusion
The clinical outcome after MWA or RFA for HCC treatment was very similar with no significant differences in LTP or OS. However, MWA shows a trend toward better DFS with fewer IDRs than RFA. Key Points:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany.
- Department of Diagnostic and Interventional Radiology, Cairo University, Faculty of Medicine, Cairo, Egypt.
Zitieren
APA
Vogl, T. J., Martin, S. S., Gruber-Rouh, T., Booz, C., Koch, V., Nour-Eldin, N. A., & Hussainy Said, M. N. (2024). Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 196(05), 482-490. https://doi.org/10.1055/a-2203-2733
Vancouver
Vogl TJ, Martin SS, Gruber-Rouh T, Booz C, Koch V, Nour-Eldin NA, et al. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2024;196(05):482-490. doi:10.1055/a-2203-2733
BibTeX
@article{Vogl2024,
author = {Vogl, Thomas J and Martin, Simon S and Gruber-Rouh, Tatjana and Booz, Christian and Koch, Vitali and Nour-Eldin, Nour-Eldin A and Hussainy Said, M N},
title = {Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial},
journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
year = {2024},
volume = {196},
number = {05},
pages = {482--490},
doi = {10.1055/a-2203-2733}
}
EUVIMED